Diversity of oxidative stress and senescence phenotypes induced by chemotherapeutic agents in HUVECs

Chemotherapy-induced endothelial cell senescence impacts tumor angiogenesis and therapy outcomes. While senescence can suppress tumorigenesis, it may also promote chronic inflammation and vascular toxicity. This study investigates how different chemotherapeutic agents induce senescence in human umbilical vein endothelial cells (HUVECs) and explores the roles of reactive oxygen species (ROS) and ataxia telangiectasia mutated (ATM) kinase. HUVECs were treated with DNA crosslinkers (doxorubicin, mitomycin C), topoisomerase inhibitors (etoposide, camptothecin), and methotrexate (MTX). Senescence was assessed via senescence-associated β-galactosidase (SA-β-gal) staining, senescence-associated secretory phenotype related factors, Phalloidin staining, immunofluorescence (p53, Ki67, 53BP1, γH2AX), mitochondrial morphology, ROS measurement, and transcriptomic sequencing. ROS scavenger Mito-Q and ATM inhibitor KU55933 were co-administered to evaluate their modulatory effects. SA-β-gal staining demonstrated that all agents induced senescence, with etoposide being the most potent (80% SA-β-gal-positive cells) and methotrexate the weakest (40%). DNA damage markers (53BP1, γH2AX) and ROS levels increased significantly, accompanied by mitochondrial fragmentation, reduced Ki67, and increased cell morphology. Furthermore, Mito-Q alleviated methotrexate-induced senescence but had no effect on other agents. ATM inhibition did not demonstrate an effect across all treatments in this study. Transcriptomic analysis revealed the p53 signaling pathway as a pivotal molecular determinant in chemotherapy-induced cellular senescence. MTX appeared mechanistically linked to TNF-mediated signaling cascades. Chemotherapeutic agents triggered endothelial senescence via DNA damage and ROS accumulation, with heterogeneity in potency and mechanisms. ROS scavengers may mitigate methotrexate-associated vascular toxicity, and targeting ROS could enhance chemotherapy safety by preserving endothelial function.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2025-10-21
DOI
https://doi.org/10.1038/s41598-025-20652-z
Primary Topic
Cancer, Hypoxia, and Metabolism
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Diversity of oxidative stress and senescence phenotypes induced by chemotherapeutic agents in HUVECs

Jiayi Dong, Yitao Yang, Kang Liu, Siming Chen et al.
Scientific Reports
Cancer, Hypoxia, and Metabolism
article

Diversity of oxidative stress and senescence phenotypes induced by chemotherapeutic agents in HUVECs

Jiayi Dong, Yitao Yang, Kang Liu, Siming Chen, Hai Xiao, Xiaojuan Zhong, Minhong Zhang
article en

Abstract

Chemotherapy-induced endothelial cell senescence impacts tumor angiogenesis and therapy outcomes. While senescence can suppress tumorigenesis, it may also promote chronic inflammation and vascular toxicity. This study investigates how different chemotherapeutic agents induce senescence in human umbilical vein endothelial cells (HUVECs) and explores the roles of reactive oxygen species (ROS) and ataxia telangiectasia mutated (ATM) kinase. HUVECs were treated with DNA crosslinkers (doxorubicin, mitomycin C), topoisomerase inhibitors (etoposide, camptothecin), and methotrexate (MTX). Senescence was assessed via senescence-associated β-galactosidase (SA-β-gal) staining, senescence-associated secretory phenotype related factors, Phalloidin staining, immunofluorescence (p53, Ki67, 53BP1, γH2AX), mitochondrial morphology, ROS measurement, and transcriptomic sequencing. ROS scavenger Mito-Q and ATM inhibitor KU55933 were co-administered to evaluate their modulatory effects. SA-β-gal staining demonstrated that all agents induced senescence, with etoposide being the most potent (80% SA-β-gal-positive cells) and methotrexate the weakest (40%). DNA damage markers (53BP1, γH2AX) and ROS levels increased significantly, accompanied by mitochondrial fragmentation, reduced Ki67, and increased cell morphology. Furthermore, Mito-Q alleviated methotrexate-induced senescence but had no effect on other agents. ATM inhibition did not demonstrate an effect across all treatments in this study. Transcriptomic analysis revealed the p53 signaling pathway as a pivotal molecular determinant in chemotherapy-induced cellular senescence. MTX appeared mechanistically linked to TNF-mediated signaling cascades. Chemotherapeutic agents triggered endothelial senescence via DNA damage and ROS accumulation, with heterogeneity in potency and mechanisms. ROS scavengers may mitigate methotrexate-associated vascular toxicity, and targeting ROS could enhance chemotherapy safety by preserving endothelial function.

Scientific ReportsVol. 15(1)
Ganzhou People's Hospital (CN), Gannan Medical University (CN), First Affiliated Hospital of Gannan Medical University (CN), Institute of Aging (CA)
Education Department of Jiangxi Province
Openalex Percentile: Top 63%
Cancer, Hypoxia, and Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.